BRINSUPRI

Launch

brensocatib

NDAORALTABLETPriority Review
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
13

Mechanism of Action

competitive, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 activates pro-inflammatory neutrophil serine proteases (NSPs) during neutrophil maturation in the bone marrow. Activated NSPs are implicated in the pathogenesis of neutrophil-mediated NCFB inflammation. In cell-based assays,…

Clinical Trials (5)

NCT06685835Phase 2Active Not Recruiting

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

Started Dec 2024
214 enrolled
Hidradenitis Suppurativa
NCT06344728Phase 1Completed

A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants

Started Apr 2024
24 enrolled
Healthy Participants
NCT06178783Phase 1Completed

A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

Started Dec 2023
20 enrolled
Healthy Volunteers
NCT06013241Phase 2Completed

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Started Oct 2023
288 enrolled
Chronic Rhinosinusitis Without Nasal Polyps
NCT05965570Phase 1Completed

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

Started Jul 2023
22 enrolled
Healthy Volunteers

Loss of Exclusivity

LOE Date
Feb 21, 2040
170 months away
Patent Expiry
Feb 21, 2040
Exclusivity Expiry
Aug 12, 2030

Patent Records (5)

Patent #ExpiryTypeUse Code
9815805
Jan 21, 2035
U-4257
10669245
Jan 21, 2035
Substance
U-4257
11655221
Jan 21, 2035
Product
U-4257
11655222
Jan 21, 2035
Substance
U-4257
11655223
Jan 21, 2035
Substance
U-4257